Lenore Arab1, David S Liebeskind. 1. David Geffen School of Medicine, Department of Medicine, UCLA, Los Angeles, 12-262 Factor, P.O. Box 951736, Los Angeles, CA 90095, USA. larab@ucla.edu
Abstract
BACKGROUND AND PURPOSE: To evaluate the strength of the in vivo evidence of relationships between flavonoids and risk of stroke. METHODS: We reviewed the literature more broadly for flavonoids and stroke and conducted an evidence-based review of original publication experiments on tea or tea components on induced coronary occlusion in animal models and on the observational epidemiology on stroke and either tea or flavonoids in man. Each of the studies was evaluated by two independent reviewers. The evidence in total was compared with the Bradford Hill [1] and Stroke Therapy Academic Industry Roundtable (STAIR)(1) quality-assessment criteria [2]. RESULTS: The search of epidemiologic publications revealed 7 cohort studies on flavonoid intake and stroke and 7 cohort studies and 3 case control studies on tea and stroke. In studies of tea there was a consistent protective effect. However, the epidemiologic research on flavonoids and stroke was much less consistent. Eleven animal experiments were identified that examined tea or tea components and stroke relevant sequelae, eight of which reported on infarct volume. All studies demonstrated reduced infarct volumes in animals exposed either to tea extracts, theanine or tea catechins prior to or shortly after reperfusion. CONCLUSIONS: Hill's criteria of causality are largely met in the case of tea and stroke. A high level of consistency across preclinical studies, of the effect of tea components as single agents effective in reducing stroke volume after middle cerebral artery occlusion, is noted in all rodent models (rat, mouse, and gerbil). Reductions in infarct volume are seen with both tea extracts consumed orally and tea components introduced intra-peritoneally. Observational epidemiology supports this finding in man for tea - the studies are consistent across countries and type of tea and the relative risks are moderately strong. That is not the case for the body of evidence on flavonoid intakes and stroke. 2010 Elsevier Inc. All rights reserved.
BACKGROUND AND PURPOSE: To evaluate the strength of the in vivo evidence of relationships between flavonoids and risk of stroke. METHODS: We reviewed the literature more broadly for flavonoids and stroke and conducted an evidence-based review of original publication experiments on tea or tea components on induced coronary occlusion in animal models and on the observational epidemiology on stroke and either tea or flavonoids in man. Each of the studies was evaluated by two independent reviewers. The evidence in total was compared with the Bradford Hill [1] and Stroke Therapy Academic Industry Roundtable (STAIR)(1) quality-assessment criteria [2]. RESULTS: The search of epidemiologic publications revealed 7 cohort studies on flavonoid intake and stroke and 7 cohort studies and 3 case control studies on tea and stroke. In studies of tea there was a consistent protective effect. However, the epidemiologic research on flavonoids and stroke was much less consistent. Eleven animal experiments were identified that examined tea or tea components and stroke relevant sequelae, eight of which reported on infarct volume. All studies demonstrated reduced infarct volumes in animals exposed either to tea extracts, theanine or tea catechins prior to or shortly after reperfusion. CONCLUSIONS: Hill's criteria of causality are largely met in the case of tea and stroke. A high level of consistency across preclinical studies, of the effect of tea components as single agents effective in reducing stroke volume after middle cerebral artery occlusion, is noted in all rodent models (rat, mouse, and gerbil). Reductions in infarct volume are seen with both tea extracts consumed orally and tea components introduced intra-peritoneally. Observational epidemiology supports this finding in man for tea - the studies are consistent across countries and type of tea and the relative risks are moderately strong. That is not the case for the body of evidence on flavonoid intakes and stroke. 2010 Elsevier Inc. All rights reserved.
Authors: Andrés Alejandro Damián-Reyna; Juan Carlos González-Hernández; Rafael Maya-Yescas; Consuelo de Jesús Cortés-Penagos; Ma Del Carmen Chávez-Parga Journal: J Food Sci Technol Date: 2017-01-30 Impact factor: 2.701
Authors: Yuji Kaneko; Lourdes Cortes; Cyndy Sanberg; Sandra Acosta; Paula C Bickford; Cesar V Borlongan Journal: Int J Mol Sci Date: 2012-06-15 Impact factor: 6.208